Bionxt Solutions Inc.
Commented by André Will-Laudien on May 22nd, 2025 | 07:20 CEST
Caution! Takeover imminent at Evotec or BioNxt, tension remains high at Bayer and Valneva
In advanced stock market cycles, many investors wonder where returns can still be made. Defense and high tech have raced ahead, and a sector rotation remains, particularly in favor of biotech. Despite substantial gains in major indices such as the DAX 40, up nearly 20%, the Nasdaq Biotech Index (NBI) is still down nearly 7%. The excitement is mounting, as some stocks are heading north and delivering better-than-expected figures. From an analytical perspective, Evotec and BioNxt are so undervalued that a takeover can no longer be ruled out. Bayer has issued a strong statement to the US courts, and Valneva is set to outperform its previous year's Q1 figures significantly. Time for an update: Where are the buying opportunities?
Read
Commented by Armin Schulz on May 14th, 2025 | 07:00 CEST
Patents, partnerships & tumor strategies: How Novo Nordisk, BioNxt Solutions, and BioNTech are securing tomorrow's profits
The global pharmaceutical industry, once the epitome of stable investments, is undergoing radical change. While protectionist trade barriers are disrupting supply chains and causing stock market prices to plummet, companies are forecasting growth for the biotech and pharmaceutical industries, according to the industry study "Life Sciences Executives Flash Report." The crisis is turning out to be a laboratory of opportunities – those who prioritize digital therapies, mRNA technologies, or sustainable production models now could emerge as winners in a reorganized market. But which strategies are convincing? We take a closer look at Novo Nordisk, BioNxt Solutions, and BioNTech.
Read
Commented by Fabian Lorenz on May 5th, 2025 | 07:00 CEST
NEW PRICE TARGET: RENK, Novo Nordisk, and takeover candidate BioNxt Solutions
Analysts are raising their price target for RENK shares significantly. However, they appear to be trailing the current share price. Things will likely get exciting at RENK on May 15, when fresh figures and, hopefully, a well-filled order book will be reported. BioNxt Solutions shares are currently of interest. Clinical trials are about to begin on the development of the leading product for the easier treatment of multiple sclerosis. The stock is cheap and seen as a hot takeover candidate - perhaps for Novo Nordisk? With simplified administration, the Danes could further accelerate sales of Ozempic and potentially reduce costs. The stock is working on a bottom, and analysts recommend it as a "Buy".
Read
Commented by Stefan Feulner on April 28th, 2025 | 11:20 CEST
BioNTech, BioNxt, Merck KGaA – Opportunities after the correction
The reporting season for the first quarter of 2025 is underway, and due to US President Donald Trump's tariff hammer, it is more exciting than ever. Investors are likely to focus primarily on forecasts for the rest of the fiscal year. Internet giant Google posted impressive figures last week and is standing firm against looming trade conflicts and antitrust proceedings. Several companies in the biotech sector also had news to report and offer attractive entry opportunities at reduced prices.
Read
Commented by Armin Schulz on April 8th, 2025 | 07:30 CEST
Bayer, BioNxt Solutions, Evotec – False tariff alarm for pharma and biotech! Which stocks are worth buying?
The provisional exemption from tariffs for medicines and pharmaceutical products offers the industry a breather – but appearances are deceptive. Based on WTO rules, the exemptions protect German exports in the multi-billion-dollar US market. However, indirect risks lurk in the form of rising costs for raw materials, political unpredictability, and dependence on global supply chains. While the sector can breathe a sigh of relief in the short term, long-term trade conflicts are forcing strategic maneuvering. For Bayer, the US market is very important. BioNxt Solutions is developing disruptive drug delivery solutions, and Evotec aims to redefine drug discovery with artificial intelligence. Let's take a closer look at these three companies.
Read
Commented by Juliane Zielonka on April 3rd, 2025 | 07:10 CEST
Novo Nordisk, BioNxt Solutions, Bayer: Three ways to health and returns
The pharmaceutical industry is booming, and three companies are set to be in the spotlight in 2025: Novo Nordisk, BioNxt Solutions, and Bayer. A common goal unites all three: To improve the health of millions of patients through innovative approaches. Investors have the opportunity to participate in their success. While their strategies differ, their focus on research, new therapies, and growth makes them exciting for investors. Novo Nordisk stands out with its obesity drug Wegovy. It reduces the risk of heart disease by 57% – a potential game changer, as obesity is a major contributor to severe cardiovascular diseases. BioNxt Solutions is leveraging fresh capital and future technologies. The Company is developing novel drug delivery systems, including sublingual films, transdermal patches, and oral tablets for autoimmune diseases like multiple sclerosis. With CAD 2.5 million from a private placement, it is ready for the next step. Bayer is pushing ahead with its broad pharmaceutical offensive. In 2025, the Leverkusen-based company will launch drugs for the treatment of cardiovascular diseases, oncology, and women's health – areas with high medical demand and market potential.
Read
Commented by Fabian Lorenz on March 25th, 2025 | 07:00 CET
Takeover speculation and buy recommendations: Buy Bayer, BioNTech, and BioNxt Solutions stock after a 150% rally?
While takeover speculations are currently on pause for Evotec, they are gaining momentum for BioNxt Solutions. The Company aims to achieve significant milestones in the next 60 days on the road to marketing its lead product for treating multiple sclerosis and expanding into the billion-dollar anti-aging market. Even after the 150% rally, BioNxt shares are not expensive. The BioNTech share has corrected sharply in 2025. However, positive analyst comments could now herald a turnaround. Will the oncology pipeline lead to a breakthrough? On the other hand, Bayer is facing a significant defeat in USD. Further billion-dollar payments are looming. Analysts remain skeptical.
Read
Commented by Stefan Feulner on March 11th, 2025 | 07:30 CET
Bayer, BioNxt Solutions, Novo Nordisk – The pressure is on
The biotech sector has started the new year with momentum, and the acquisition wave is heating up, as confirmed by Johnson & Johnson's acquisition of Intra-Cellular Therapies for USD 15 billion. The trend will likely continue as major pharmaceutical companies are under massive pressure to strengthen their portfolios. After all, drug patents worth over USD 200 billion will expire by the end of the decade. This will force the giants to make strategic acquisitions.
Read
Commented by André Will-Laudien on March 3rd, 2025 | 07:35 CET
Biotech: Takeover candidates for 2025! Things are heating up at Evotec, BioNxt, Bayer, and Formycon!
The DAX 40 index is hitting new highs, following a gigantic wave of buying from the US. The rally is already well advanced, but due to ongoing geopolitical upheavals, high-tech and defense stocks are still performing well. In recent weeks, the positive trends have also spread to the biotech sector again. Stocks such as BioNxt have already gained over 150% in the last six months. What is driving this? Formycon has seen a severe price drop, while Bayer and Evotec are slowly getting back on track. Are we going to see takeovers now? What are the triggers for dynamic investors?
Read
Commented by Armin Schulz on February 27th, 2025 | 07:30 CET
Bayer, BioNxt Solutions, Evotec – Artificial intelligence as a gamechanger in pharmaceutical research
New technologies and innovative solutions will completely transform the future of medicine. To prepare for this as well as possible, hurdles such as bureaucracy, financial issues, and outdated structures must be overcome. At the same time, management must set the course, as development is continuing at a rapid pace – whether through artificial intelligence (AI) in drug research or customized therapies for individual patients. One thing is clear: anyone who wants to keep up here must think differently. But how are companies tackling this in practice? Three examples reveal why flexibility and fresh ideas are crucial right now for staying ahead in the long term.
Read